MD Valuation

Pediatrix Medical Group Inc

Add to Watchlist

Advanced Chart

17.210

+0.11(0.643%)1D

Overview
Forecast
Valuation
Earnings

MD Relative Valuation

MD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, MD is overvalued; if below, it's undervalued.

Historical Valuation

Pediatrix Medical Group Inc (MD) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.58 is considered Undervalued compared with the five-year average of 11.16. The fair price of Pediatrix Medical Group Inc (MD) is between 24.09 to 35.95 according to relative valuation methord. Compared to the current price of 17.21 USD , Pediatrix Medical Group Inc is Undervalued By 28.56%.

Relative Value

Fair Zone

24.09-35.95

Current Price：17.21

28.56%

Undervalued

9.58

Trailing

Forward

6.98

EV/EBITDA

Pediatrix Medical Group Inc. (MD) has a current EV/EBITDA of 6.98. The 5-year average EV/EBITDA is 8.96. The thresholds are as follows: Strongly Undervalued below 4.02, Undervalued between 4.02 and 6.49, Fairly Valued between 11.44 and 6.49, Overvalued between 11.44 and 13.91, and Strongly Overvalued above 13.91. The current Forward EV/EBITDA of 6.98 falls within the Historic Trend Line -Fairly Valued range.

7.72

EV/EBIT

Pediatrix Medical Group Inc. (MD) has a current EV/EBIT of 7.72. The 5-year average EV/EBIT is 10.69. The thresholds are as follows: Strongly Undervalued below 4.73, Undervalued between 4.73 and 7.71, Fairly Valued between 13.67 and 7.71, Overvalued between 13.67 and 16.65, and Strongly Overvalued above 16.65. The current Forward EV/EBIT of 7.72 falls within the Historic Trend Line -Fairly Valued range.

0.77

Pediatrix Medical Group Inc. (MD) has a current PS of 0.77. The 5-year average PS is 0.76. The thresholds are as follows: Strongly Undervalued below 0.12, Undervalued between 0.12 and 0.44, Fairly Valued between 1.08 and 0.44, Overvalued between 1.08 and 1.40, and Strongly Overvalued above 1.40. The current Forward PS of 0.77 falls within the Historic Trend Line -Fairly Valued range.

8.61

P/OCF

Pediatrix Medical Group Inc. (MD) has a current P/OCF of 8.61. The 5-year average P/OCF is 12.88. The thresholds are as follows: Strongly Undervalued below -5.46, Undervalued between -5.46 and 3.71, Fairly Valued between 22.05 and 3.71, Overvalued between 22.05 and 31.23, and Strongly Overvalued above 31.23. The current Forward P/OCF of 8.61 falls within the Historic Trend Line -Fairly Valued range.

11.66

P/FCF

Pediatrix Medical Group Inc. (MD) has a current P/FCF of 11.66. The 5-year average P/FCF is 16.04. The thresholds are as follows: Strongly Undervalued below -14.96, Undervalued between -14.96 and 0.54, Fairly Valued between 31.53 and 0.54, Overvalued between 31.53 and 47.03, and Strongly Overvalued above 47.03. The current Forward P/FCF of 11.66 falls within the Historic Trend Line -Fairly Valued range.

Pediatrix Medical Group Inc (MD) has a current Price-to-Book (P/B) ratio of 1.76. Compared to its 3-year average P/B ratio of 1.28 , the current P/B ratio is approximately 37.79% higher. Relative to its 5-year average P/B ratio of 1.79, the current P/B ratio is about -1.77% higher. Pediatrix Medical Group Inc (MD) has a Forward Free Cash Flow (FCF) yield of approximately 15.45%. Compared to its 3-year average FCF yield of 12.41%, the current FCF yield is approximately 24.44% lower. Relative to its 5-year average FCF yield of 10.21% , the current FCF yield is about 51.26% lower.

1.76

P/B

Median3y

1.28

Median5y

1.79

15.45

FCF Yield

Median3y

12.41

Median5y

10.21

Competitors Valuation Multiple

The average P/S ratio for MD's competitors is 1.23, providing a benchmark for relative valuation. Pediatrix Medical Group Inc Corp (MD) exhibits a P/S ratio of 0.77, which is -37.42% above the industry average. Given its robust revenue growth of -7.03%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

MD.N

Pediatrix Medical Group Inc

Aveanna Healthcare Holdings Inc

US Physical Therapy Inc

Performance Decomposition

Market capitalization of MD increased by 48.49% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 4.70 to 13.30.

The secondary factor is the Revenue Growth, contributed -7.03%to the performance.

Overall, the performance of MD in the past 1 year is driven by P/E Change. Which is more unsustainable.

-7.03%

504.30M → 468.84M

Revenue Growth

-127.59%

-30.34 → 8.37

Margin Expansion

183.11%

4.70 → 13.30

P/E Change

48.49%